Reports Q1 revenue $52.6M, consensus $53.86M. “The Company is off to a solid start to the year, with record first quarter MACI revenue and total Company revenue, and continued strength in the key performance indicators for the MACI Arthro launch,” said Nick Colangelo, President and CEO of Vericel (VCEL). “Based on the positive trends across the business to start the second quarter, we expect strong revenue growth and profitability in the second quarter and for the remainder of the year as the Company is well-positioned for continued high revenue and profit growth in 2025 and beyond.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- VCEL Earnings this Week: How Will it Perform?
- Vericel Shareholders Approve Key Proposals at Annual Meeting
- Vericel’s Strong Market Position and Growth Prospects Drive Buy Rating Amid Economic Resilience
- Vericel price target lowered to $60 from $63 at BTIG
- Vericel Sees Minimal Impact from U.S. Tariffs